Page last updated: 2024-09-02

tamibarotene and ER-Negative PR-Negative HER2-Negative Breast Cancer

tamibarotene has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bansal, N; Bosch, A; Cubedo, E; Farias, E; Fishel, M; Jones, JW; Kane, M; Leibovitch, B; Pereira, L; Pierzchalski, K; Waxman, S; Yu, J; Zelent, A	1

Other Studies

1 other study(ies) available for tamibarotene and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Animals; Antineoplastic Agents; Benzoates; Carcinogenesis; Cell Line, Tumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Receptors, Retinoic Acid; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Tetrahydronaphthalenes; Thiazoles; Triple Negative Breast Neoplasms	2016

Article

Year

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.

Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

Topics: Animals; Antineoplastic Agents; Benzoates; Carcinogenesis; Cell Line, Tumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Receptors, Retinoic Acid; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Tetrahydronaphthalenes; Thiazoles; Triple Negative Breast Neoplasms

2016